Incidence and characterization of fungal infections in chronic lymphocytic leukemia patients receiving ibrutinib
Michael Frei, Samuel L Aitken, Nitin Jain, Philip A. Thompson, William G. Wierda, Dimitrios P. Kontoyiannis, Adam J. DiPippo
Abstract
Ibrutinib, a first-generation inhibitor of Bruton’s tyrosine kinase (BTK), is an important therapeutic option in chronic lymphocytic leukemia (CLL) [1]. In clinical trials, invasive fungal infectio...
Topics & Concepts
IbrutinibChronic lymphocytic leukemiaBruton's tyrosine kinaseMedicineLeukemiaIncidence (geometry)Tyrosine kinaseInternal medicineImmunologyOncologyReceptorPhysicsOpticsChronic Lymphocytic Leukemia ResearchImmunodeficiency and Autoimmune DisordersAntifungal resistance and susceptibility